«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:

2012年第4期

页码:

446-449

栏目:

临床研究

出版日期:

2012-08-25

文章信息/Info

Title:

Distribution of adiponectin multimers and their relationship with cardiovascular risk factors in patients with hypercholesterolemia

作者:

王文清¹; 李 榕²; 陈 迈³; 王晓明²; 邢文娟⁴; 张海锋⁵; 尚 磊⁶

(第四军医大学：1.唐都医院血液内科，2.西京医院老年病科，3.西京医院心内科，4.基础部生理学教研室，5.基础部教学实验中心，6.统计学教研室，陕西 西安 710032)

Author(s):

WANG Wen-qing¹;  LI Rong²;  CHEN Mai³;  WANG Xiao-ming²;  XING Wen-juan⁴;  ZHANG Hai-feng⁵;  SHANG Lei⁶

(1.Department of Hematology, Tangdu Hospital, 2.Department of Geriatrics, Xijing Hospital, 3.Department of Cardiology, Xijing Hospital, 4.Department of Physiology, 5.Center of Teaching Experiments, 6.Department of Statistics, Fourth Military Medical University, Xi’an 710032, China)

关键词:

脂联素; 高胆固醇血症; 冠状动脉疾病; 危险因素

Keywords:

adiponectin multimers;  high molecular weight adiponectin;  hypercholesterolemia;  cardiovascular disease;  cardiovascular risk factors

分类号:

R541.4

DOI:

-

文献标识码:

A

摘要:

目的:探讨血循环中不同分子量多聚体形式的脂联素（APN）在高胆固醇血症患者中的分布及其与冠心病的相关性。方法： 研究对象包括148例男性高胆固醇血症患者，按是否并发冠心病又分为单纯高胆固醇组（n=68）和并发冠心病组（n=80）,另选年龄及体质量指数（BMI）与高胆固醇组相匹配的健康查体者（健康对照组，n=84）。排除糖尿病、高血压病、肾脏疾病及重度吸烟人群。结果： 与健康对照组相比，高分子量APN和中分子量APN在单纯高胆固醇组显著增加［高分子量APN亚组:(4.98±0.87) mg/L vs. (2.51±0.33) mg/L,P<0.01;中分子量APN亚组:(2.20±0.36) mg/L vs.(1.01±0.15) mg/L,P<0.01］,而在并发冠心病组患者中显著降低，且与健康对照组无显著差异。与其它APN多聚体相比，高分子量APN与冠心病相关心血管危险因素——总胆固醇（TC,r=0.345,P<0.05）、高密度脂蛋白胆固醇（HDL-C,r=0.325,P<0.05）及尿酸（UA,r=-0.472,P<0.01）水平密切相关。Logistic回归分析显示高分子量APN是高胆固醇血症患者发生冠心病的独立危险因素（OR,8.43;P<0.05）。结论： 高胆固醇血症患者中高分子量APN水平的降低与并发冠心病有相关性。

Abstract:

AIM:To determine the circulatory distribution of hormone adiponectin (APN) multimers and their relationships with cardiovascular disease (CVD)-related biochemical indicators in patients with hypercholesterolemia (HC). METHODS: A total of 148 age- and body mass index (BMI)-matched male patients with HC (80 with CVD and 68 without CVD) and 84 healthy male controls were enrolled. Diabetes mellitus, hypertension, nephropathy and smoking habit constituted exclusion criteria. RESULTS: Both high molecular weight (HMW) and medium molecular weight (MMW) forms of APN significantly increased in HC without CVD (HMW: 4.98±0.87 vs. 2.51±0.33 in controls, P<0.01; MMW: 2.20±0.36 vs. 1.01±0.15 in control, P<0.01) and were comparable to those in patients with HC-related CVD (HCVD). In comparison to other APN oligomers, HMW was most closely associated with the HCVD-related biochemical factors: total cholesterol (r=0.345, P<0.05), high-density lipoprotein cholesterol (HDLc, r=0.325, P<0.05) and uric acid (UA, r=-0.472, P<0.01). Additional analysis via binary logistic regression suggested HMW APN was an independent predictor of risk for HCVD (OR, 8.434; P=0.018). CONCLUSION: Reduced HMW isoform concentrations may predict the possibility of cardiovascular complications in HC patients.

参考文献/References

[1]Pajvani UB,Du X,Combs TP,et al.Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity[J].J Biol Chem,2003,278(11):9073-9085.

[2]Goldstein BJ,Scalia RG,Ma XL.Protective vascular and myocardial effects of adiponectin[J].Nat Clin Pract Cardiovasc Med,2009,6(1):27-35.

[3]Kumada M,Kihara S,Sumitsuji S,et al.Association of hypoadiponectinemia with coronary artery disease in men[J].Arterioscler Thromb Vasc Biol,2003,23(1):85-89.

[4]Kanety H,Hemi R, Ginsberg S,et al.Total and high molecular weight adiponectin are elevated in patients with Laron syndrome despite marked obesity[J].Eur J Endocrinol,2009,161(6):837-844.

[5]Li R,Xu M,Wang X,et al.Reduced vascular responsiveness to adiponectin in hyperlipidemic rats--mechanisms and significance[J].J Mol Cell Cardiol,49(3):508-515.

[6]Satoh H,Fujii S,Tsutsui H.The high-molecular weight(HMW)form of adiponectin is a significant surrogate marker for the prediction of type 2 diabetes mellitus in the Japanese population[J].Nutr Metab Cardiovasc Dis,20(3):e9- e10.

[7]中国临床血脂控制达标行动专家组.提高临床血脂控制达标率的专家建议[J].中华心血管病杂志,2010, 38(4):294-298.

[8]Kadowaki T,Yamauchi T,Kubota N,et al.Adiponectin and adiponectin receptors in insulin resistance, diabetes,and the metabolic syndrome[J].J Clin Invest,2006, 116(7):1784-1792.

[9]Kanety H,Hemi R,Ginsberg S,et al.Total and high molecular weight adiponectin are elevated in patients with Laron syndrome despite marked obesity[J].Eur J Endocrinol, 2009,161(6):837-844.

[10]Mullen KL,Smith AC,Junkin KA,et al.Globular adiponectin resistance develops independently of impaired insulin-stimulated glucose transport in soleus muscle from high-fat-fed rats[J].Am J Physiol Endocrinol Metab,2007,293(1):E83- E90.

[11]Mullen KL,Pritchard J,Ritchie I,et al.Adiponectin resistance precedes the accumulation of skeletal muscle lipids and insulin resistance in high-fat-fed rats[J].Am J Physiol Regul Integr Comp Physiol,2009,296(2):R243-251.

[12]Kanety H,Hemi R,Ginsberg S,et al.Total and high molecular weight adiponectin are elevated in patients with Laron syndrome despite marked obesity[J].Eur J Endocrinol,2009,161(6):837-844.

[13]Wang ZV,Schraw TD,Kim JY,et al.Secretion of the adipocyte-specific secretory protein adiponectin critically depends on thiol-mediated protein retention[J].Mol Cell Biol,2007, 27(10):3716-3731.

[14]Koenen TB,van Tits LJ,Holewijn S,et al.Adiponectin multimer distribution in patients with familial combined hyperlipidemia[J].Biochem Biophys Res Commun,2008,376(1):164-168.

[15]Lau WB,Tao L,Wang Y,et al.Systemic adiponectin malfunction as a risk factor for cardiovascular disease[J].Antioxid Redox Signal,15(7):1863-1873.

[16]Baldwin W,McRae S,Marek G,et al.Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome[J].Diabetes, 60(4):1258-1269.

备注/Memo

备注/Memo:

收稿日期：2011-01-30.基金项目：教育部留学回国人员科研启动基金资助（HG2401）通讯作者：李榕，主治医师，主要从事代谢综合征发病机制及防治研究Email：rongli.li09@gmail.com 共同通讯作者：陈迈，主治医师，主要从事心肌细胞损伤与修复研究Email：chenmai@fmmu.edu.cn 作者简介：王文清，主治医师，博士Email：scwwq@yahoo.com.cn

常用功能

更新日期/Last Update: 2012-07-20